135
Participants
Start Date
May 26, 2015
Primary Completion Date
November 28, 2018
Study Completion Date
October 29, 2019
Mycophenolate Mofetil Placebo
MMF matching placebo will be administered orally Q12H.
Mycophenolate Mofetil
MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
Rituximab
Rituximab will be administered at a dose of 1000 mg via IV infusion.
Rituximab Placebo
Rituximab matching placebo will be administered via IV infusion.
Hospital Austral, Pilar, Pcia de Buenos Aires
Centro de Investigaciones Médicas - CIM, San Juan Bautista
St George Hospital, Kogarah, New South Wales
Veracity Clinical Research, Woolloongabba
Hospital Luis Lagomaggiore, Mendoza
Icahn School of Medicine at Mount Sinai, New York
S.C. Dermatologia 2 - Ambulatorio Malattie Rare, Turin
Uni of NY and Roswell Cancer, Buffalo
HaEmek MC, Afula
Penn University, Philadelphia
University Hospital Schleswig-Holstein, Lübeck
ASST DEGLI SPEDALI CIVILI DI BRESCIA; Clinica Dermatologica, Brescia
U.O. Dermatologia Dipartimento Malattie Infettive Fondazione IRCCS Policlinico San Matteo, Pavia
Wake Forest Baptist Hospital Center for Dermatology Research, Winston-Salem
Hosp. G. U Gregorio Marañón, Madrid
Hospital de la Victoria, Málaga
Clinica Universitaria de Navarra, Pamplona
Rambam Medical Centre; Dept. of Dermatology, Haifa
CHU Hopitaux de Bordeaux, CHU Hopitaux de Bordeaux
Bezm-i Alem University Medical Faculty, Istanbul
Istanbul Uni Istanbul Medical Faculty, Istanbul
Haydarpasa Numune Training and Research Hospital, Istanbul
CHU de Rennes - Hopital de Pontchaillo, Rennes
University of Alabama Birmingham, Birmingham
CHU Saint Etienne - Hôpital Nord, Saint-Etienne
Cleveland Clinic, Cleveland
Celal Bayar University Medical Faculty Hafsa Sultan Hospital, Manisa
University of Munster, Münster
Rabin Medical Centre; Dept. of Dermatology, Petah Tikva
Ambulatorio di Malattie Rare e Immunopatologia Cutanea, Florence
Klinik und Poliklinik für Dermatologie und Venerologie Universitätsklinikum Köln, Cologne
CHU de Reims, Reims
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Hautklinik und Poliklinik, Mainz
University of Minnesota, Minneapolis
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille
Northwestern University, Chicago
St Louis University Hospital, St Louis
Universitätsklinikum Heidelberg, Heidelberg
Les Hospices Civils de Lyon Dermatologie inflammatoire et médecine interne, Lyon / Pierre Bénite
CHU de Rouen - Hôpital Charles Nicolle, Rouen
Kompetenzzentrum Fragile Haut Klinik fur Dermatologie und Venerologie, Freiburg im Breisgau
University of Arizona Medical Research Office, Tucson
Los Angeles Biomedical Research Institute, Torrance
Department of Dermatology Avicenne Hospital & University, Bobigny
Univ of Calif-San Francisco, San Francisco
UC Davis Department of Dermatology, Sacramento
Oregon Health Sciences Uni, Portland
Sheba Medical Center, Ramat Gan
Sourasky Medical Centre, Tel Aviv
Massachusetts General Hospital Dermatology, Boston
Hospital Italiano, Buenos Aires
Faculdade de Medicina de Botucatu - Hospital das Clínicas, Botucatu
Santa Casa de São Paulo Hospital Central X, São Paulo
Hospital das Clinicas - FMUSP, São Paulo
University of Alberta, Edmonton
Guildford Dermatology, Surrey
Lynde Institute for Dermatology, Markham
University Hospital for Dermatology, Dresden
Università di Parma Clinica Dermatologica, Parma
Gülhane Military Medical Academy in Ankara, Ankara
Gaziantep University Medical Faculty Sahinbey Hospital, Gaziantep
Marmara Uni, Istanbul
Karadeniz Teknik Üniversitesi Tıp Fakültesi Farabi Hastanesi, Trabzon
Dnipropetrovsk State Medical Academy, Dnipropterovsk
Centro Clinico per le genodermatosi Dipartimento di Dermatologia dell'Immacolata - IRCCS, Rome
Hospital Clínic. Barcelona, Barcelona
Akdeniz University Medical Faculty, Antalya
"Territorial Medical Association Dermatovenerologia", Kyiv
Collaborators (1)
Genentech, Inc.
INDUSTRY
Hoffmann-La Roche
INDUSTRY